Ampio Pharmaceuticals Inc.
05/17/2022 | Press release | Distributed by Public on 05/17/2022 10:35
Ampio Pharmaceuticals Reports First-Quarter Financial Results
Ampio Pharmaceuticals
Ampio Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for prevalent inflammatory conditions for which limited treatment options exist. We are advancing immunology-based therapies to provide safe and effective treatments for patients suffering from these diseases.
Our lead product, Ampion™, is a biologic drug that uses the power of the immune response to address the underlying causes of inflammatory disease. Ampion is designed to provide anti-inflammatory relief to safely treat persistent inflammation and improve the lives of people with debilitating diseases, like osteoarthritis, respiratory illness, and other inflammatory conditions.
Ampion is manufactured in our modern, state of the art facility, which has been designed to meet international regulatory standards with the capacity to supply global demand.
Ampion and COVID-19
Ampion may interrupt the hyperinflammatory response and respiratory disease associated with COVID-19. Clinical trials are being conducted to evaluate the safety and efficacy of Ampion treatment for patients with COVID-19.
Ampion and Osteoarthritis
Ampion reduces pain and improves function in patients with severe osteoarthritis of the knee (OAK). The clinical program for OAK is in late phase clinical trials for filing a marketing application.
Ampion regulates the immune response
Ampion uses the power of the immune response and is in development to treat osteoarthritis, respiratory illness due to COVID-19, and a wide range of other debilitating and life-threatening inflammatory conditions.